These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 10169621)
21. [Resistance to activated protein C disclosed by postphlebitic disease. Two cases]. Foueré S; Lestang P; Cosnes A; Gouault-Heilmann M; Revuz J Ann Dermatol Venereol; 1996; 123(1):24-5. PubMed ID: 8734112 [TBL] [Abstract][Full Text] [Related]
22. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Dahlbäck B Thromb Haemost; 1995 May; 73(5):739-42. PubMed ID: 7482395 [No Abstract] [Full Text] [Related]
23. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251 [TBL] [Abstract][Full Text] [Related]
24. [Clinical usefulness of global assays of the anticoagulant pathway of protein C]. Toulon P Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384 [TBL] [Abstract][Full Text] [Related]
25. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Weitz IC; Israel VK; Liebman HA Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031 [TBL] [Abstract][Full Text] [Related]
26. Resistance to activated protein C and a novel factor V gene mutation. Voelkerding KV Clin Lab Med; 1996 Mar; 16(1):169-86. PubMed ID: 8867589 [TBL] [Abstract][Full Text] [Related]
27. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review. Jespersen J Eur J Contracept Reprod Health Care; 1996; 1(1):3-11. PubMed ID: 9678132 [TBL] [Abstract][Full Text] [Related]
28. Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis. Dahlbäck B Rev Invest Clin; 1997 May; 49 Suppl 1():3-5. PubMed ID: 9291738 [No Abstract] [Full Text] [Related]
29. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis. Gessoni G; Valverde S Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946 [TBL] [Abstract][Full Text] [Related]
30. [A new hereditary cause of portal vein thrombosis: the abnormal resistance to activated protein C by the Arg 506-->Gln mutation of the gene of factor V]. Levoir D; Aubertin JM; Alhenc-Gelas M; Bloch F; Becheur H; Petite JP Gastroenterol Clin Biol; 1995; 19(8-9):729-31. PubMed ID: 8522125 [TBL] [Abstract][Full Text] [Related]
31. [Activated protein C resistance in factor V disease: how high is the risk of thrombosis?]. Spannagl M; Schramm W Dtsch Med Wochenschr; 1998 Feb; 123(6):137-9. PubMed ID: 9505951 [No Abstract] [Full Text] [Related]
32. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Martinelli I; Legnani C; Bucciarelli P; Grandone E; De Stefano V; Mannucci PM Thromb Haemost; 2001 Sep; 86(3):800-3. PubMed ID: 11583310 [TBL] [Abstract][Full Text] [Related]
33. Inherited Thrombophilia due to Factor V Leiden Mutation. Mattson JC; Crisan D Mol Diagn; 1998 Mar; 3(1):55-61. PubMed ID: 10096958 [TBL] [Abstract][Full Text] [Related]
34. Resistance to activated protein C as a basis for venous thrombosis. Svensson PJ; Dahlbäck B N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317 [TBL] [Abstract][Full Text] [Related]
35. [Resistance to activated protein C. The most common cause of familial thrombophilia]. Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822 [TBL] [Abstract][Full Text] [Related]
36. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)]. Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526 [TBL] [Abstract][Full Text] [Related]
38. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. Zöller B; Svensson PJ; He X; Dahlbäck B J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612 [TBL] [Abstract][Full Text] [Related]
39. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene. Nowak-Göttl U; Sträter R; Dübbers A; Oleszuk-Raschke K; Vielhaber H Blood Coagul Fibrinolysis; 1996 Oct; 7(7):684-8. PubMed ID: 8958390 [TBL] [Abstract][Full Text] [Related]
40. [National evaluation of the diagnosis of activated protein C resistance]. Montiel-Manzano G; de la Peña-Díaz A; Majluf-Cruz A; Cesarman-Maus G; Corona-de la Peña N; Cruz-Cruz D; Gaminio E; Martínez-Murillo C; Mayagoitia T; Miranda-Peralta E; Poblete T; Quintana-Martínez S; Ramírez R; Razo D; Ruiz de Chávez-Ochoa A; Reyes-Núñez VA; Salazar R; Vicencio-Santiago GV; Villa R Rev Invest Clin; 2003; 55(3):358-69. PubMed ID: 14515684 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]